78
Views
0
CrossRef citations to date
0
Altmetric
Review

The reimbursement process in three national healthcare systems: variation in time to reimbursement of pembrolizumab for metastatic non-small cell lung cancer

ORCID Icon, , , , &
Article: 22 | Received 08 Dec 2022, Accepted 07 Feb 2023, Published online: 11 Mar 2024

Figures & data

Table 1 Comparison of the reimbursement process for three healthcare services

Table 2 Dates of approval and reimbursement of pembrolizumab

Availability of data and materials

Not applicable.